Home > Resources > Videos > Medicine's next revolution | Alan Cassels | TEDxVictoria

Medicine's next revolution | Alan Cassels | TEDxVictoria

A drug policy researcher for the University of Victoria, Alan Cassels is a known for having a knack for finding and describing the chasm between what the market says and what science does in modern healthcare. Over the past two decades Cassels has spent much of his research energy studying clinical research and the marketing tactics of the pharmaceutical industry, turnin

Spotlight

Bridge Therapeutics Inc.

Bridge Therapeutics®, based in Birmingham, Ala., is an innovative development-stage specialty pharmaceutical company pursuing U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) approvals of a patented (U.S. Patent #8410092) drug combination, BT-205, for the treatment of chronic pain in opioid-experienced patients. The investigational drug BT-205 is a unique combination of two synergistic chronic pain drugs—the partial-agonist opioid buprenorphine and the NSAID meloxicam—delivered in a state-of-the-art sublingual formulation.

OTHER VIDEOS

The Cardinal Health™ InteLogix™ Platform

video | September 6, 2023

Learn about the industry’s first pharmaceutical supply chain solution that is reducing the cost of care and ensuring access to critical medications for hospitals and health systems....

Watch Now

Aeris: Benchtop XRD for pharmaceutical solid form analysis

video | August 28, 2023

Is solid form characterization critical in your line of work, but you lack expertise in X-ray diffraction (XRD)? Do you need an efficient tool to support you with lead optimization? Do you need an easy way to validate the stability of your solid form following processing?...

Watch Now

Semi-automated testing of on-body delivery systems (OBDS)

video | August 17, 2023

Injection systems that are attached to the patient's body (on-body delivery system OBDS) minimize possible risks, that can occur when drugs are administered by conventional needle-based injection systems (NIS)....

Watch Now

Line Optimizer - digital guided workflows for optimized pharma production operations

video | May 26, 2023

Connectivity in general is becoming an ever more important consideration for production facilities as we endeavour to produce more with less and all the while trying to satisfy an increasing need for more information and communication to and from the production equipment itself....

Watch Now

The Cardinal Health™ InteLogix™ Platform

video | September 6, 2023

Learn about the industry’s first pharmaceutical supply chain solution that is reducing the cost of care and ensuring access to critical medications for hospitals and health systems....

Watch Now

Aeris: Benchtop XRD for pharmaceutical solid form analysis

video | August 28, 2023

Is solid form characterization critical in your line of work, but you lack expertise in X-ray diffraction (XRD)? Do you need an efficient tool to support you with lead optimization? Do you need an easy way to validate the stability of your solid form following processing?...

Watch Now

Semi-automated testing of on-body delivery systems (OBDS)

video | August 17, 2023

Injection systems that are attached to the patient's body (on-body delivery system OBDS) minimize possible risks, that can occur when drugs are administered by conventional needle-based injection systems (NIS)....

Watch Now

Line Optimizer - digital guided workflows for optimized pharma production operations

video | May 26, 2023

Connectivity in general is becoming an ever more important consideration for production facilities as we endeavour to produce more with less and all the while trying to satisfy an increasing need for more information and communication to and from the production equipment itself....

Watch Now
MORE VIDEOS

Spotlight

Bridge Therapeutics Inc.

Bridge Therapeutics®, based in Birmingham, Ala., is an innovative development-stage specialty pharmaceutical company pursuing U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) approvals of a patented (U.S. Patent #8410092) drug combination, BT-205, for the treatment of chronic pain in opioid-experienced patients. The investigational drug BT-205 is a unique combination of two synergistic chronic pain drugs—the partial-agonist opioid buprenorphine and the NSAID meloxicam—delivered in a state-of-the-art sublingual formulation.

Events